Literature DB >> 27468889

Evaluating the consequences of rheumatoid arthritis.

Björn Sossong1, Stefan Felder2, Malte Wolff3, Klaus Krüger4.   

Abstract

Patients and non-patients tend to attach different utility values to the state of suffering from specific illnesses. This observation naturally leads to the question whose utility values should be used as the basis in cost-effectiveness analysis (CEA). Intuitively, one would presume that patients are better informed about the consequences of their illness, and public authorities should, therefore, use the patients' utility values in CEA. Contrary to this presumption, it has been argued that society at large should determine which values are to be used and not the patients because, in the end, it is societal resources that are to be allocated. Against this background, we use data from a discrete choice experiment (DCE) that was completed by patients of rheumatoid arthritis (RA) and non-patients to explore the discrepancies between the two groups' utility estimates for typical consequences of RA. Our results indicate that both groups attach remarkably similar part-worth utilities to the symptoms pain, fatigue, and functional limitations. However, non-patients significantly undervalue the ability to work when compared to patients.

Entities:  

Keywords:  Cost-effectiveness analysis; Discrete choice experiment; Rheumatoid arthritis

Mesh:

Year:  2016        PMID: 27468889     DOI: 10.1007/s10198-016-0818-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  35 in total

1.  'Irrational' stated preferences: a quantitative and qualitative investigation.

Authors:  Fernando San Miguel; Mandy Ryan; Mabelle Amaya-Amaya
Journal:  Health Econ       Date:  2005-03       Impact factor: 3.046

2.  Deleting 'irrational' responses from discrete choice experiments: a case of investigating or imposing preferences?

Authors:  Emily Lancsar; Jordan Louviere
Journal:  Health Econ       Date:  2006-08       Impact factor: 3.046

Review 3.  Valuing health States for use in cost-effectiveness analysis.

Authors:  John Brazier
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis.

Authors:  Richard Charles John Campbell; Michael Batley; Anthony Hammond; Fowzia Ibrahim; Gabrielle Kingsley; David L Scott
Journal:  Clin Rheumatol       Date:  2011-11-29       Impact factor: 2.980

5.  The impact of passive coping on rheumatoid arthritis pain.

Authors:  T Covic; B Adamson; M Hough
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

6.  Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis.

Authors:  P A Ubel; J Richardson; P Menzel
Journal:  Health Econ       Date:  2000-03       Impact factor: 3.046

7.  Sensitivity and perspective in the valuation of health status: whose values count?

Authors:  G A De Wit; J J Busschbach; F T De Charro
Journal:  Health Econ       Date:  2000-03       Impact factor: 3.046

8.  Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis.

Authors:  John R Kirwan; Sarah Hewlett
Journal:  J Rheumatol       Date:  2007-05       Impact factor: 4.666

9.  The prevalence and meaning of fatigue in rheumatic disease.

Authors:  F Wolfe; D J Hawley; K Wilson
Journal:  J Rheumatol       Date:  1996-08       Impact factor: 4.666

10.  Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities.

Authors:  Yvette Peeters; Anne M Stiggelbout
Journal:  Value Health       Date:  2009-09-10       Impact factor: 5.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.